Coastal Investment Advisors Inc. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 31.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,027 shares of the biopharmaceutical company’s stock after buying an additional 9,746 shares during the period. Coastal Investment Advisors Inc.’s holdings in Pfizer were worth $1,506,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Nordea Investment Management AB boosted its holdings in shares of Pfizer by 65.3% during the 2nd quarter. Nordea Investment Management AB now owns 22,272,402 shares of the biopharmaceutical company’s stock valued at $719,176,000 after acquiring an additional 8,798,233 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Pfizer by 74.8% in the second quarter. Two Sigma Advisers LP now owns 11,066,501 shares of the biopharmaceutical company’s stock worth $361,875,000 after purchasing an additional 4,736,500 shares during the last quarter. APG Asset Management N.V. lifted its stake in Pfizer by 129.4% in the first quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock worth $227,038,000 after purchasing an additional 3,924,241 shares during the last quarter. BlackRock Inc. raised its stake in shares of Pfizer by 0.8% during the second quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock valued at $13,980,372,000 after acquiring an additional 3,464,207 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Pfizer by 8,940.8% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,426,457 shares of the biopharmaceutical company’s stock valued at $112,045,000 after acquiring an additional 3,388,557 shares in the last quarter. 69.08% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:PFE traded up $0.75 during midday trading on Friday, hitting $38.18. 28,992,325 shares of the company’s stock traded hands, compared to its average volume of 20,809,482. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The company has a market cap of $212.16 billion, a PE ratio of 15.15, a P/E/G ratio of 3.10 and a beta of 0.66. The firm’s fifty day moving average price is $36.59 and its two-hundred day moving average price is $36.49. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is 51.53%.
PFE has been the subject of a number of research analyst reports. UBS Group increased their price target on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $44.00 to $39.00 in a research report on Monday, October 12th. SVB Leerink raised their price objective on Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a report on Wednesday, July 29th. ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Finally, Mizuho reaffirmed a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Tuesday, September 15th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $39.81.
In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, with a total value of $501,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at $154,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What sectors are represented in the Hang Seng index?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.